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Abstract
Background—Although dobutamine stress echocardiography (DSE) is performed in heart
transplant patients, the safety profile of atropine administration in DSE in this setting is unclear.
Methods and Results—We identified heart transplant patients who received atropine during
DSE from January 1984 to August 2011 at our institution and compared them with a propensity-
scored matched control group of heart transplant patients who underwent DSE without atropine.
Adverse events were defined as significant arrhythmias (sinus arrest, Mobitz type II heart block,
complete heart block, ventricular tachycardia, or ventricular fibrillation), hypotension requiring
hospitalization, syncope or presyncope, myocardial infarction, and death. Forty-five heart
transplant patients (median age 62 years, 82% male) received 0.2–1 mg atropine during DSE. Of
these, 1 patient (2.2%) developed temporary complete heart block. No adverse events were
identified in the control group of 154 patients who received dobutamine without atropine.
Conclusions—Our findings suggest that complete heart block can occur infrequently with the
administration of atropine in heart transplant patients undergoing DSE. Therefore, patients should
be appropriately monitored for these adverse events during and after DSE.
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Invasive coronary angiography is the recommended primary method for detecting allograft
coronary artery disease (CAD) in patients who have undergone orthotopic heart
transplantation.1 Nevertheless, dobutamine stress echocardiography (DSE) is commonly
performed as an alternate modality that can provide complementary assessment of functional
perfusion.2–10 When dobutamine alone is insufficient to achieve target heart rate during
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stress echocardiography, atropine can be administered to augment the heart rate
response.5,7,11 However, evidence from small studies suggests that adverse events can occur
with the use of atropine in heart transplant patients, including sinus arrest or complete heart
block that can result in syncope or require ventricular pacing.12,13 Notably, none of those
studies were conducted in the setting of concurrent dobutamine infusion. Previous reports of
heart transplant patients who received atropine during DSE did not report any significant
side effects, but these studies were small and did not primarily examine the safety profile of
atropine when given concurrently with dobutamine.5,11,14–17 To examine whether atropine
can be safely administered during DSE, we examined the use of atropine during DSE for
heart transplant patients at our institution.
Methods
Study Design
We used the electronic health record (EHR) to retrospectively identify all heart transplant
patients who underwent DSE with atropine at the Columbia University Medical Center
(CUMC) from January 1, 1984, to August 18, 2011, and selected as control subjects
propensity score–matched heart transplant patients who underwent DSE without atropine
during the same time period. To accomplish this, we queried DSE reports of all heart
transplant patients followed at CUMC during that time period with the use of the terms
“dobutamine” and “atropine.” From all heart transplant recipients, we identified 2,157
patients who had undergone DSE and of these 45 patients who received both dobutamine
and atropine. Of these 45 patients, each underwent exactly 1 DSE during which they
received atropine. To identify a suitable control population, we randomly selected a group of
400 transplant patients who underwent DSE but did not receive atropine. Using a
standardized data extraction template for both groups (heart transplant patients that received
dobutamine and atropine during DSE, and those who received dobutamine only), we
manually abstracted from the medical record each patient’s demographic and medical
covariates at the time of DSE, including age, sex, time since transplant, beta-blocker use,
calcium channel blocker use, and history of known transplant CAD (based on left heart
catheterization). We performed nearest-neighbor propensity score matching18,19 on the 400
randomly selected heart transplant patients who underwent DSE but did not receive atropine
to further identify a subset of 154 patients who were matched to those who received both
dobutamine and atropine on the aforementioned baseline characteristics (age, sex, time from
transplant, beta-blocker use, calcium channel blocker use, and known transplant CAD). For
patients in the control group who had undergone >1 DSE, the most recent DSE was included
for analysis. The results did not change when earlier DSE studies were used in the analyses
for these patients. We then abstracted height, weight, body mass index (BMI), left
ventricular ejection fraction (LVEF), history of hypertension, diabetes, or ischemic
cardiomyopathy, existing bundle branch block (defined as QRS duration >120 ms) before
DSE, and use of immunosuppressants (including corticosteroids, tacrolimus,
mycophenolate, sirolimus, and cyclosporine) for all 45 atropine recipients and 154
propensity score–matched patients who did not receive atropine during DSE.
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Dobutamine Stress Echocardiography Protocol
For DSE, a standard protocol was used for all patients, beginning with dobutamine infusion
at 10 μg kg−1 min−1 and increasing by 10 μg kg−1 min−1 every 3 minutes, until a maximum
infusion rate of 40 μg kg−1 min−1. For patients who also received atropine, 0.2–1 mg
atropine was administered during the final stage. All patients were monitored by
electrocardiogram and blood pressure recordings during DSE and monitored on telemetry
for ~1 hour after DSE was completed. We abstracted baseline and peak heart rates and the
doses of dobutamine and atropine administered. For adverse outcomes, all patients were
monitored for occurrence of adverse events until time of discharge to home, and we
manually searched the EHR for any events that occurred within 30 days after DSE for each
patient, defined a priori as clinically significant arrhythmias (sinus arrest, Mobitz type II or
complete heart block, ventricular tachycardia, or ventricular fibrillation), hypotension
requiring hospitalization, syncope or presyncope, myocardial infarction, and death. None of
the participants were lost to follow-up during this period.
Statistical Analysis
Demographic and clinical characteristics were compared for patients who received atropine
during DSE and for those who did not. Demographic characteristics that were compared
include age, sex, and time since transplant. Clinical characteristics that were compared
include BMI, presence of diabetes and hypertension, ischemic cardiomyopathy before
transplantation, presence of baseline bundle branch block, LVEF, use of beta-blockers and
calcium channel blockers, and presence of transplant CAD based on catheterization. We
examined all variables for normality of distribution. In addition, we compared DSE test
characteristics, including dobutamine dose, heart rate at rest and peak heart rate, and number
of adverse events during DSE between the 2 groups. For normally distributed variables,
Pearson chi-square tests or Fisher exact tests were used for comparison between categoric
variables, and independent t tests were used for continuous variables. For non-normally
distributed variables, nonparametric testing with the use of the Mann-Whitney U test was
performed for comparison. A P value of <.05 was considered to be statistically significant.
All calculations were performed with the use of the statistical packages IBM SPSS Statistics
for Windows 17.0 and Stata IC version 10. Propensity score matching was performed using
the Stata module psmatch2 by Leuven and Sianesi.20
Results
Of the 45 heart transplant patients who received dobutamine and atropine during DSE, the
median (25th–75th percentiles) age at DSE was 62 (49–69) years, and the median (25th–
75th percentiles) time between heart transplantation and DSE was 7 (4–10) years. Thirty-
seven patients (82%) were male. As expected, the propensity score– matched control group
of heart transplant patients who received dobutamine without atropine was not significantly
different from the group who received both dobutamine and atropine in age, sex, time since
heart transplantation, beta-blocker and calcium channel blocker usage, and known transplant
CAD. Other baseline patient characteristics also were similar, including BMI, comorbidities,
immunosuppressive medications, prevalence of baseline bundle branch block, and LVEF
(Table 1).
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In the group that received dobutamine and atropine, each patient underwent exactly 1 DSE
in which they received both medications. These 45 patients all received a maximum rate of
dobutamine infusion at 40 μg kg−1 min−1; 24 (53%) of the 45 heart transplant patients
received a maximum dose of 1 mg atropine. The median (25th–75th percentiles) dose of
atropine received was 1 (0.5–1) mg, corresponding to a weight-based dose of 0.01 (0.006–
0.013) mg/kg. In the group that received dobutamine without atropine (Table 2), the median
(25th–75th percentiles) maximum rate of dobutamine infusion was 30 (20–40) μg kg−1
min−1, which was significantly lower than the dose of dobutamine in patients who did not
receive atropine (P < .005). Compared with patients who received both dobutamine and
atropine, patients who received dobutamine without atropine had significantly higher resting
and peak heart rates (P < .005 for both), and were more likely to achieve maximum
predicted heart rate for age (MPHR) of 80% (P < .005) and 85% (P < .005; Fig. 1; Table 2).
Regarding adverse events, of the 45 heart transplant patients who received dobutamine and
atropine, 1 patient (2.2%) experienced complete heart block along with ventricular asystole
20 seconds after receiving 0.5 mg (0.01 mg/kg) atropine, leading to hypotension and
syncope (Fig. 2). This patient was a 55-year-old woman 12 years after transplantation with
normal allograft cardiac function, baseline right bundle branch block, and no known history
of coronary disease, bradycardia, complete heart block, syncope, or hypotension. Chest
compressions were administered within 5 seconds of heart block and the patient reverted to
normal sinus rhythm with gradual recovery of consciousness. The patient was subsequently
hospitalized and an electrophysiology study was conducted the following day which showed
no conduction block at or below the level of the His bundle and no evidence of intrinsic
conduction disease. She was discharged without further events or need for pacemaker
implantation. The remaining 44 patients did not experience any adverse clinical events
during or after DSE, and no events were identified within 30 days of DSE. No adverse
events were identified in the control group for any of the DSEs performed during the follow-
up period.
Discussion
The present study represents one of the largest cohort of heart transplant patients who
received atropine during DSE and the first to primarily focus on the safety of atropine
administration during dobutamine infusion. We examined the use of atropine during DSE in
heart transplant patients in a real-world clinical setting, and we found that atropine
administration was associated with complete heart block, an infrequent yet idiosyncratic
adverse event.
The paradoxic complete heart block induced by atropine alone without dobutamine in heart
transplant patients has been described previously.12,13 Brunner–la Rocca et al reported that 3
(13%) of 23 heart transplant patients who received atropine without dobutamine developed
syncope with 2nd-degree atrioventricular block or complete heart block 15–150 minutes
after receiving atropine.12 Similarly, a study by Bernheim et al showed that atropine
administration without dobutamine was associated with complete heart block and sinus
arrest in 5 (20%) out of 25 patients in a non–dose-dependent manner, and the lowest
atropine dose associated with an adverse event was 0.004 mg/kg.13 Our results extend the
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findings of those earlier studies by examining the risk of complete heart block with atropine
in heart transplant patients undergoing concurrent administration of dobutamine.
A few studies of atropine use in heart transplant patients undergoing DSE have been
conducted, but they were smaller and did not primarily focus on the risk of adverse
events.5,11,14–17 A retrospective study by Kociolek et al included 21 transplant patients who
received atropine during DSE, and a similar study by Flox et al included 14 transplant
patients who also received both agents.11,16 The patient populations in those studies were
similar to ours, though the study by Flox et al did not include patients using beta-blockers.
Although there were slight protocol differences, such as higher doses of atropine and
dobutamine in the study by Kociolek et al, no adverse events were reported in either study.
In contrast, our study, which primarily focused on the safety of atropine administration in
heart transplant patients undergoing DSE, found a possible, but low, risk of paradoxic heart
block.
Although several studies have associated atropine with causing bradycardia in
nontransplanted patients,21–23 reports of atropine associated with high-degree
atrioventricular (AV) block are rare.24–26 One study described a patient who was
administered atropine for anesthesia-induced sinus arrest,26 and another case study
described a patient that was administered atropine for anesthesia-induced sinus
bradycardia24; both patients developed high-degree AV block (though not complete heart
block) after atropine was given. A third case-series described 12 patients who developed
Mobitz type I heart block in the setting of acute inferior wall myocardial infarction; 3 of
those patients developed complete heart block after atropine was administered.25 In all 3
studies, confounding by indication may have contributed to the results: Atropine was given
to patients who had acutely abnormal AV conduction, and therefore the association between
atropine and high-degree heart block may merely be a consequence of the deteriorating
condition of the patients. In contrast, the present study describes the development of
complete heart block after atropine administration in a heart transplant patient receiving
dobutamine and whose rhythm was stable.
There is currently no standard recommended duration of monitoring in heart transplant
patients once DSE has been completed, particularly for those patients that received
atropine.27,28 Atropine has a longer half-life (2–3 h) than dobutamine (2 min).22 In our
study, the one adverse event occurred 20 seconds after receiving atropine. However, given
the half-life of atropine, and the idiosyncratic nature of the adverse event, it may be prudent
for heart transplant patients who receive atropine to be monitored closely not only during
DSE, but also during the period immediately after DSE.
The mechanism of the paradoxic heart block in heart transplant patients who receive
atropine is unknown, but earlier investigators speculated that alterations in receptor response
to atropine after heart transplantation may be responsible.12,13 It has been theorized that
changes in muscarinic receptor expression or function may occur after heart transplantation,
leading to a parasympathomimetic response after atropine administration.12 Alternatively, it
has been suggested that atropine could decrease automaticity and prolong the atrial
refractory period in poorly re-innervated transplanted hearts.29
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Although our study is focused on safety rather than on efficacy of atropine as a chronotropic
agent, we did find that only 2 (4.5%) of 45 patients achieved heart rate ≥85% MPHR, which
is lower than the findings of earlier studies.11,16 This difference could be due in part to
protocol differences such as the maximum doses of dobutamine and atropine that were
given. Doses of dobutamine and atropine for each patient in our study were determined by
the supervising physician. Of the 45 patients, 16 (36%) were able to achieve ≥80% MPHR.
As there is some evidence suggesting that this heart rate (80% MPHR) provides adequate
sensitivity for detecting CAD in heart transplant patients,4,17 it is possible that physicians at
our institution may have targeted a lower maximum heart rate during DSE.
Our study has several possible limitations. Our study is a retrospective analysis of DSE in
heart transplant patients performed at a single center, and the dosing of atropine was left at
the discretion of the supervising physician for each DSE, which may limit the
generalizability of our finding to other institutions. However, the dose of atropine used in
our study is similar to or lower than those used in earlier studies, suggesting that the risk of
complete heart block may occur even with judicious atropine dosing. It is possible that we
did not capture short episodes of complete heart block that occurred hours or more after
atropine administration when patients were not monitored. However, we searched for events
up to a month after each DSE in our EHR, making it unlikely that any episodes of heart
block that we missed would have been clinically significant.
In conclusion, the present study represents one of the largest studies to examine the safety of
atropine administration during DSE in heart transplant patients. Our results suggest that in
the presence of a chronotropic agent such as dobutamine, complete heart block can occur as
an infrequent and idiosyncratic reaction to atropine in heart transplant patients. We
recommend that patients who receive atropine should be appropriately monitored after DSE
to detect these adverse events. Future studies are needed to better characterize the efficacy of
using atropine to augment heart rate response in heart transplant patients undergoing DSE.
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Distribution of maximum heart rates expressed as maximum predicted heart rate for age in
heart transplant patients who did and did not receive atropine during dobutamine stress
echocardiography. Percentage of patients represents the percentage within each group of
patients.
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Rhythm strip (lead II) of a heart transplant patient with complete heart block with
ventricular asystole, recorded 20 seconds after atropine was administered during dobutamine
stress echocardiography.
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Table 1
Patient Characteristics
Patients Who Did Not
Receive Atropine (n = 154)
Patients Who Did
Receive Atropine (n =
45) P Value*
Median age, y (25–75th percentiles) 61 (51.5–70.5) 62 (49–69) .55
Median time since transplant at time of DSE, y (25–75th percentiles) 7 (3.5–12) 7 (4–10) .69
Male gender, n (%) 134 (87%) 37 (82%) .62
Mean BMI, kg/m2 (SD) 27.7 (4.9) 28.0 (5.4) .73
Diabetes, n (%) 81 (53%) 22 (49%) .66
Hypertension, n (%) 67 (44%) 20 (44%) .91
Ischemic cardiomyopathy before heart transplantation, n (%) 50 (33%) 16 (39%) .30
On beta-blocker, n (%) 49 (32%) 15 (36%) .85
On calcium channel blocker, n (%) 20 (13%) 4 (21%) .46
Baseline bundle branch block, n (%) 33 (21%) 7 (16%) .39
Mean no. of immunosuppressants (SD) 2.7 (0.5) 2.7 (0.5) .47
Mean left ventricular ejection fraction, % (SD) 56 (8) 56 (7) .94
Has transplant CAD by catheterization, n (%) 9 (5.8%) 2 (4.4%) .72
BMI, body mass index; CAD, coronary artery disease, DSE, dobutamine stress echocardiography.
*
P values were calculated with the use of chi-square tests for categoric variables and Student t tests for continuous variables, except for age and
time since transplantation, for which Mann-Whitney U tests were used owing to skewed distributions.
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Table 2
Test Characteristics in Heart Transplant Patients Who Did and Did Not Receive Atropine During DSE
Patients Who Did Not
Receive Atropine (n = 154)
Patients Who Did Receive
Atropine (n = 45) P Value*
Median maximum dobutamine dose, μg kg−1 min−1 (25–75th
percentiles)
30 (20–40) 40† <.005
Mean heart rate at rest, bpm (SD) 86 (12) 76 (9) <.005
Mean peak heart rate, bpm (SD) 135 (17) 123 (14) <.005
Mean peak heart rate, % MPHR (SD) 85 (9) 76 (7) <.005
Achieved 80% MPHR, n (%) 128 (83%) 16 (36%) <.005
Achieved 85% MPHR, n (%) 97 (63%) 2 (4.5%) <.005
bpm, beats per minute; MPHR, maximum predicted heart rate for age.
*
P values were calculated with the use of chi-squared tests for categoric variables and Student t tests for continuous variables, except for
dobutamine dose, for which Mann-Whitney U tests were used owing to skewed distributions.
†All patients in this group received 40 μg kg−1 min−1.
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